Celsion Corporation (CLSN)

[cameron12x]

RE: Poon and Lencioni Presentations

These presentations are already available at the Celsion website under News and Investor Info. You can download the PowerPoint for each presentation there.

I've reviewed the presentations and there really is nothing really new to report in the slides. The only takeaway that I could see is that a new trial will likely be needed with specific controls around RFA ablation time. (There were no such controls in Phase III, which was a big mistake.) As such, I believe the FDA will recommend another P3 trial. I could be wrong, but I don't believe there is NOT enough data available now even for limited approval in the U.S.

Asia, however, is another story. The overall trial consisted of 701 patients and was broken out as follows: (USA/Canada: 30, Italy: 49, Asia: 622). And fully 30% of the overall trial enrollment came directly from China. That makes the agreement with Hisun all the more understandable. It remains to be seen what will be needed to market the drug in Chinese or Asian markets. That is the key, however, to any short-term sustainable gains in the stock price. All of the rest is simply hope, conjecture, and day trading, IMHO.
I hope that something "big" comes out of the European conference from either Poon or Lencioni, but after reading their actual public presenatations, I only have tempered and limited enthusiasm.

GLTA!